Johnson & Johnson Announces New Two-year Results From Its Phase 3 ICONIC-LEAD Study Evaluating ICOTYDE In Adults With Moderate-To-Severe Plaque Psoriasis; Data Demonstrated Consistently High Levels Of Skin Clearance And Patient-Reported Symptom Improvement At Week 112, With No New Safety Signals

ICOTYDE clinical data highlights2

• High levels of skin clearance were observed at Week 112, with ≥72% of ICOTYDE-treated patients achieving a Psoriasis Area and Severity Index score (PASI)c of 90 and ≥70% achieving clear or almost clear skin (Investigator's Global Assessment [IGA]d 0/1) from Week 64 through Week 112.
• Complete skin clearance was sustained from Week 64 through Week 112, with ≥44% of ICOTYDE-treated patients achieving PASI 100 and ≥46% achieving IGA 0 (clear skin).
• Clinically meaningful improvement in itch was sustained in 78% of patients from Week 64 to Week 112.
• Among PASI 90 responders who were withdrawn from ICOTYDE at Week 24, 85% regained PASI 90 response within 24 weeks of retreatment.
• Safety findings through Week 112 remained consistent with the established safety profile of ICOTYDE, with no new safety signals identified.